Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia patients. The authors compared mortality with pimavanserin and atypical antipsychotics in a large database. METHODS: This was a retrospective new-user cohort study of Medicare beneficiaries with Parkinson's disease initiating pimavanserin (N=3,227) or atypical antipsychotics (N=18,442) from April 2016 to March 2019. All-cause mortality hazard ratios and 95% confidence intervals were estimated for pimavanserin compared with atypical antipsychotics, using segmented proportional hazards regression over 1-180 and 181+ days of treatment. Potential confounding was addressed through inverse probability of treatment weighting (IPTW). RESULTS: Pimavanserin users had a mean age of approximately 78 years, and 45% were female. Before IPTW, some comorbidities were more prevalent in atypical antipsychotic users; after IPTW, comorbidities were well balanced between groups. In the first 180 days of treatment, mortality was approximately 35% lower with pimavanserin than with atypical antipsychotics (hazard ratio=0.65, 95% CI=0.53, 0.79), with approximately one excess death per 30 atypical antipsychotic-treated patients; however, during treatment beyond 180 days, there was no additional mortality advantage with pimavanserin (hazard ratio=1.05, 95% CI=0.82, 1.33). Pimavanserin showed no mortality advantage in nursing home patients. CONCLUSIONS: Pimavanserin use was associated with lower mortality than atypical antipsychotic use during the first 180 days of treatment, but only in community-dwelling patients, not nursing home residents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A US retrospective cohort study comparing pimavanserin (n=3227) with atypical antipsychotics (n=18442) in Parkinson's disease with or without dementia, found a 35% lower mortality rate in those treated with pimavanserin(539).”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [539]
Citations
Cites
Frailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Prevalence of Parkinson’s disease across North America
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0058-0 · Cited by 968
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Xie, J., & Liu, C. (2005) · Statistics in Medicine · doi:10.1002/sim.2174 · Cited by 510
Epidemiology of psychosis in Parkinson's disease
Fénelon, G., & Alves, G. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.014 · Cited by 330
What predicts mortality in Parkinson disease?: A prospective population-based long-term study
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., & Alves, G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f61311 · Cited by 302
Development of a Claims-based Frailty Indicator Anchored to a Well-established Frailty Phenotype
Segal, J. B., Chang, H.-Y., Du, Y., Walston, J. D., Carlson, M. C., & Varadhan, R. (2017) · Medical Care · doi:10.1097/mlr.0000000000000729 · Cited by 244
Longitudinal outcome of Parkinson’s disease patients with psychosis
Factor, S. A., Feustel, P. J., Friedman, J. H., Comella, C. L., Goetz, C. G., Kurlan, R., Parsa, M., Pfeiffer, R., & the Parkinson Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000068010.82167.cf · Cited by 234
Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease
Weintraub, D., Chiang, C., Kim, H. M., Wilkinson, J., Marras, C., Stanislawski, B., Mamikonyan, E., & Kales, H. C. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0031 · Cited by 168
Hwang, Y. J., Alexander, G. C., An, H., Moore, T. J., & Mehta, H. B. (2021) · Neurology · doi:10.1212/wnl.0000000000012601 · Cited by 46
The US Food and Drug Administration’s Perspective on the New Antipsychotic Pimavanserin
Mathis, M. V., Muoio, B. M., Andreason, P., Avila, A. M., Farchione, T. R., Atrakchi, A. H., & Temple, R. J. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16r11119 · Cited by 44
Horn, S. R. G.-V., Richardson, H., Xie, S. X., Weintraub, D. A., & Dahodwala, N. A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.11.009 · Cited by 42
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine
Moreno, G. J., Gandhi, R., Lessig, S. L., Wright, B. A., Litvan, I., & Nahab, F. B. (2018) · Neurology · doi:10.1212/wnl.0000000000006396 · Cited by 37
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study
Yuan, M., Sperry, L., Malhado-Chang, N., Duffy, A., Wheelock, V., Farias, S. T., O'Connor, K. M., Olichney, J., Shahlaie, K., & Zhang, L. (2017) · Brain and Behavior · doi:10.1002/brb3.639 · Cited by 22
Tibshirani (1997) · doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
Research works printed but not linked: 1
- Pennap D, 2020, Pharmacoepidemiol Drug Saf, 29, 401
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Dementia Prevention and Treatment: A Narrative Review
Reuben, D. B., Kremen, S., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 202
Mantovani, E., Zucchella, C., Argyriou, A. A., & Tamburin, S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2173576 · Cited by 37
Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
Rissardo, J. P., Durante, Í., Sharon, I., & Caprara, A. L. F. (2022) · Brain Sciences · doi:10.3390/brainsci12101286 · Cited by 27
Yunusa, I. U., Rashid, N., Seyedin, R., Paratane, D., & Rajagopalan, K. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231154933 · Cited by 28
Metadata
- Authors
- Mosholder, A. D., Ma, Y., Akhtar, S., Podskalny, G. D., Feng, Y., Lyu, H., Liao, J., Wei, Y., Wernecke, M., Leishear, K., Nelson, L. M., MaCurdy, T. E., Kelman, J. A., & Graham, D. J.
- Affiliations
- United States Food and Drug Administration (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2022-08-01
- Volume
- 179
- Issue
- 8
- Pages
- 553-561
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4282958777
- Cited by
- 33
- References
- 21
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 11 · 2023: 7 · 2022: 7
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- pimavanserin, atypical antipsychotics, Parkinson's disease psychosis, mortality, all-cause mortality, delusions and hallucinations, nursing home residents, community-dwelling patients, inverse probability of treatment weighting, Medicare beneficiaries
- MeSH terms
- Aged, Female, Medicare, Humans, Male, Parkinson Disease, Piperidines, Psychotic Disorders, Retrospective Studies, Antipsychotic Agents, United States, Urea, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.